Understanding how BRCA1 or BRCA2 mutation-associated genomic instability and tumor heterogeneity contribute towards TGF-β-induced EndMT could pave the way for the development of more effective treatment strategies aimed at targeting not only cancer cells and their tumor microenvironment but also different CVDS in BRCA1/2-mutant individuals. The gene discussed is TGFB1; the disease is neoplasm.